Sanghavi, RiaPana, Tiberiu A.Mamayusupova, HulkarMaidment, IanFox, ChrisBoekholdt, S MatthijsMamas, Mamas AWareham, Nicholas J.Khaw, Kay TeeMyint, Phyo Kyaw2022-06-142022-06-142022-07-01Sanghavi, R, Pana, T A, Mamayusupova, H, Maidment, I, Fox, C, Boekholdt, S M, Mamas, M A, Wareham, N J, Khaw, K T & Myint, P K 2022, 'Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study', British Journal of Clinical Pharmacology, vol. 88, no. 7, pp. 3297-3306. https://doi.org/10.1111/bcp.152610306-5251ORCID: /0000-0002-1423-8111/work/107908265ORCID: /0000-0003-3852-6158/work/163198880https://hdl.handle.net/2164/18711Acknowledgements: We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. We would also like to acknowledge the principal investigators and staff of the EPIC-Norfolk study. Funding The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) was funded by the Medical Research Council, Grant number (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK, Grant number (C864/A14136).101361751engSDG 3 - Good Health and Well-beingAnticholinergicsfibrinogenC-Reactive ProteinTumour Necrosis Factor-alphaInterleukin-6cardiovascular diseasesR MedicineMedical Research Council (MRC)MR/N003284/1MC-UU_12015/1Cancer Research UKC864/A14136Supplementary DataRJournal article10.1111/bcp.15261887